RIVAROXABAN PRECISION DOSING STRATEGY FOR REAL-WORLD ATRIAL FIBRILLATION PATIENTS.

被引：0
|
作者：
Powell, J. [1 ]
Konicki, R. [1 ]
Weiner, D. [1 ]
Patterson, J. [1 ]
Gonzalez, D. [1 ]
机构：
[1] Univ N Carolina, Chapel Hill, NC 27515 USA
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2020年 / 107卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
PIII-084
引用
收藏
页码：S100 / S101
页数：2
相关论文
共 50 条
  • [31] Clinical impact of inappropriate DOAC dosing in atrial fibrillation: Insights from a real-world registry
    Yildirim, Mustafa
    Hund, Hauke
    Mueller-Hennessen, Matthias
    Katus, Hugo A.
    Frey, Norbert
    Giannitsis, Evangelos
    Salbach, Christian
    IJC HEART & VASCULATURE, 2025, 56
  • [32] Real-world performance of the atrial fibrillation monitor in patients with a subcutaneous ICD
    Baalman, Sarah W. E.
    Mittal, Suneet
    Boersma, Lucas V. A.
    Perschbacher, Dave
    Brisben, Amy J.
    Mahajan, Deepa
    Groot, Joris R.
    Knops, Reinoud E.
    PACE-PACING AND CLINICAL ELECTROPHYSIOLOGY, 2020, 43 (12): : 1467 - 1475
  • [33] Ischaemic stroke and bleeding rates in 'real-world' atrial fibrillation patients
    Ogilvie, Isla M.
    Welner, Sharon A.
    Cowell, Warren
    Lip, Gregory Y. H.
    THROMBOSIS AND HAEMOSTASIS, 2011, 106 (01) : 34 - 44
  • [34] Real-world comparison of bleeding risks among non-valvular atrial fibrillation patients prescribed apixaban, dabigatran, or rivaroxaban
    Tepper, Ping G.
    Mardekian, Jack
    Masseria, Cristina
    Phatak, Hemant
    Kamble, Shital
    Abdulsattar, Younos
    Petkun, William
    Lip, Gregory Y. H.
    PLOS ONE, 2018, 13 (11):
  • [35] Real-World Outcomes of Rivaroxaban Treatment in Patients with Both Nonvalvular Atrial Fibrillation and a History of Ischemic Stroke/Transient Ischemic Attack
    Minematsu, Kazuo
    Ikeda, Takanori
    Ogawa, Satoshi
    Kitazono, Takanari
    Nakagawara, Jyoji
    Miyamoto, Susumu
    Murakawa, Yuji
    Takeichi, Makiko
    Kidani, Yoko
    Okayama, Yutaka
    Sunaya, Toshiyuki
    Sato, Shoichiro
    Yamanaka, Satoshi
    CEREBROVASCULAR DISEASES, 2019, 48 (1-2) : 53 - 60
  • [36] Real-world variability in dabigatran levels in patients with atrial fibrillation: comment
    Douxfils, J.
    Chatelain, B.
    Dogne, J. -M.
    Mullier, F.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2015, 13 (06) : 1166 - 1168
  • [37] Real-world variability in dabigatran levels in patients with atrial fibrillation: reply
    Chan, N. C.
    Hirsh, J.
    Ginsberg, J. S.
    Eikelboom, J. W.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2015, 13 (06) : 1168 - 1169
  • [38] Impact of body mass index on real-world outcomes of rivaroxaban treatment in Japanese patients with non-valvular atrial fibrillation
    Murakawa, Yuji
    Ikeda, Takanori
    Ogawa, Satoshi
    Kitazono, Takanari
    Nakagawara, Jyoji
    Minematsu, Kazuo
    Miyamoto, Susumu
    Hayashi, Yasuhiro
    Kidani, Yoko
    Okayama, Yutaka
    Sunaya, Toshiyuki
    Sato, Shoichiro
    Yamanaka, Satoshi
    HEART AND VESSELS, 2020, 35 (08) : 1125 - 1134
  • [39] Impact of body mass index on real-world outcomes of rivaroxaban treatment in Japanese patients with non-valvular atrial fibrillation
    Yuji Murakawa
    Takanori Ikeda
    Satoshi Ogawa
    Takanari Kitazono
    Jyoji Nakagawara
    Kazuo Minematsu
    Susumu Miyamoto
    Yasuhiro Hayashi
    Yoko Kidani
    Yutaka Okayama
    Toshiyuki Sunaya
    Shoichiro Sato
    Satoshi Yamanaka
    Heart and Vessels, 2020, 35 : 1125 - 1134
  • [40] Safety and efficacy of apixaban, dabigatran and rivaroxaban in obese and morbidly obese patients with heart failure and atrial fibrillation: A real-world analysis
    Chugh, Yashasvi
    Gupta, Kashvi
    Krishna, Hanumanthu Balram
    Ayala, Renato Quispe
    Zepeda, Ignacio
    Grushko, Michael
    Faillace, Robert T.
    PACE-PACING AND CLINICAL ELECTROPHYSIOLOGY, 2023, 46 (01): : 50 - 58
12345